Histone deacetylase

Acetylation of histones and transcription-related factors.
[10839822] Microbiol Mol Biol Rev 64(2): 435-59 (2000)

HDAC inhibitors: a potential new category of anti-tumor agents.
[17976313] Cell Mol Immunol 4(5): 337-43 (2007)

The molecular mechanism of HDAC inhibitors in anticancer effects.
[16978537] Cell Mol Immunol 3(4): 285-90 (2006)

Inhibition of histone deacetylase activity by butyrate.
[12840228] J Nutr 133(7 Suppl): 2485S-2493S (2003)

HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics.
[17325692] Cell Res 17(3): 195-211 (2007)

Histone deacetylase inhibitors: a novel target of anticancer therapy (review).
[16391874] Oncol Rep 15(2): 489-94 (2006)

Histone deacetylase inhibitors as novel anticancer therapeutics.
[19008999] Curr Oncol 15(5): 237-43 (2008)

Competitive or noncompetitive, that's the question: research toward histone deacetylase inhibitors.
[18483291] Mol Cancer Ther 7(5): 1007-12 (2008)

Mechanisms of resistance to histone deacetylase inhibitors and their therapeutic implications.
[18094401] Clin Cancer Res 13(24): 7237-42 (2007)

The clinical application of targeting cancer through histone acetylation and hypomethylation.
[15269129] Clin Cancer Res 10(14): 4589-96 (2004)

Dietary HDAC inhibitors: time to rethink weak ligands in cancer chemoprevention?
[16267097] Carcinogenesis 27(2): 344-9 (2006)

Histone deacetylase inhibitors: overview and perspectives.
[17951399] Mol Cancer Res 5(10): 981-9 (2007)

The role of histone deacetylases (HDACs) in human cancer.
[19383284] Mol Oncol 1(1): 19-25 (2007)

Histone deacetylase inhibitors: apoptotic effects and clinical implications (Review).
[18813776] Int J Oncol 33(4): 637-46 (2008)

Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents.
[20132536] J Hematol Oncol 3(-): 5 (2010)

New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer.
[19486511] J Hematol Oncol 2(-): 22 (2009)

Class IIa histone deacetylases: conducting development and differentiation.
[19412888] Int J Dev Biol 53(2-3): 291-301 (2009)

Histone deacetylase HDAC1/HDAC2-controlled embryonic development and cell differentiation.
[19412887] Int J Dev Biol 53(2-3): 275-89 (2009)

Histone acetylation modifiers in the pathogenesis of malignant disease.
[11055583] Mol Med 6(8): 623-44 (2000)

Deciphering NAD-dependent deacetylases.
[11336664] Cell 105(2): 161-4 (2001)

What's up and down with histone deacetylation and transcription?
[9150131] Cell 89(3): 325-8 (1997)

Targeting chromatin disruption: Transcription regulators that acetylate histones.
[8601304] Cell 84(6): 817-9 (1996)

[Epidemic of keratokonjunctivitis at the IInd Eye Clinic in Prague during 1974-1975].
[963794] Cesk Oftalmol 32(4): 307-10 (1976)

Dissecting histone deacetylase function.
[12079776] Chem Biol 9(6): 668-70 (2002)

Acetylation of general transcription factors by histone acetyltransferases.
[9285713] Curr Biol 7(9): 689-92 (1997)

Transcriptional control: calling in histone deacetylase.
[9259549] Curr Biol 7(8): R505-7 (1997)

Histone acetyltransferases in control.
[9081669] Curr Biol 7(2): R82-4 (1997)

The origin and utility of histone deacetylases.
[9428625] FEBS Lett 419(2-3): 157-60 (1997)

Histone deacetylase. A key enzyme for the binding of regulatory proteins to chromatin.
[8425601] FEBS Lett 317(3): 175-80 (1993)

Enhanced histone acetylation and transcription: a dynamic perspective.
[16885019] Mol Cell 23(3): 289-96 (2006)

Structure of histone deacetylases: insights into substrate recognition and catalysis.
[11738039] Structure 9(12): 1127-33 (2001)

On the biological role of histone acetylation.
[2405837] Biochem J 265(1): 23-38 (1990)

Histone-deacetylase inhibitors for the treatment of cancer.
[15153801] Cell Cycle 3(6): 779-88 (2004)

Control of cardiac growth by histone acetylation/deacetylation.
[16397154] Circ Res 98(1): 15-24 (2006)

The role of histone deacetylases in prostate cancer.
[19029799] Epigenetics 3(6): 300-9 (2008)

HDACs and HDAC inhibitors in colon cancer.
[18326939] Epigenetics 3(1): 28-37 (2008)

Clinical potential of histone deacetylase inhibitors as stand alone therapeutics and in combination with other chemotherapeutics or radiotherapy for cancer.
[17965606] Epigenetics 1(3): 121-6 (2006)

Rationale for the use of histone deacetylase inhibitors as a dual therapeutic modality in multiple sclerosis.
[17998807] Epigenetics 1(2): 67-75 (2006)

Histone deacetylase inhibitors for cancer therapy.
[17998811] Epigenetics 1(1): 14-23 (2006)

Histone acetylation and deacetylation: importance in inflammatory lung diseases.
[15738302] Eur Respir J 25(3): 552-63 (2005)

Transcriptional control at regulatory checkpoints by histone deacetylases: molecular connections between cancer and chromatin.
[11257101] Hum Mol Genet 10(7): 693-8 (2001)

Simple histone acetylation plays a complex role in the regulation of gene expression.
[16980317] Brief Funct Genomic Proteomic 5(3): 190-208 (2006)

Epigenetic regulators and histone modification.
[16951415] Brief Funct Genomic Proteomic 5(3): 222-7 (2006)

Histone acetylation in gene regulation.
[16877467] Brief Funct Genomic Proteomic 5(3): 209-21 (2006)

Histone acetylation and control of gene expression.
[1757496] J Cell Sci 99 ( Pt 1)(-): 13-20 (1991)

Histone deacetylase inhibitors in cancer therapy.
[12673114] Cancer Biol Ther 2(1): 30-7 (2003)

Targeting histone deacetylase activity in rheumatoid arthritis and asthma as prototypes of inflammatory disease: should we keep our HATs on?
[18983693] Arthritis Res Ther 10(5): 226 (2008)

Potential non-oncological applications of histone deacetylase inhibitors.
[22046487] Am J Transl Res 3(5): 454-67 (2011)

Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs.
[21416059] Am J Transl Res 3(2): 166-79 (2011)

SIRT1-dependent regulation of chromatin and transcription: linking NAD(+) metabolism and signaling to the control of cellular functions.
[19879981] Biochim Biophys Acta 1804(8): 1666-75 (2010)

Roles of dynamic and reversible histone acetylation in plant development and polyploidy.
[17556080] Biochim Biophys Acta 1769(5-6): 295-307 (2007)

Nitric oxide-mediated epigenetic mechanisms in developing neurons.
[19221483] Cell Cycle 8(5): 725-30 (2009)

Protein acetylation in the cardiorenal axis: the promise of histone deacetylase inhibitors.
[20133912] Circ Res 106(2): 272-84 (2010)

Histone deacetylase enzymes as potential drug targets in cancer and parasitic diseases.
[16883049] J Biomed Biotechnol 2006(2): 13474 (2006)

Autophagic and apoptotic effects of HDAC inhibitors on cancer cells.
[21629704] J Biomed Biotechnol 2011(-): 830260 (2011)

Therapeutic strategies to enhance the anticancer efficacy of histone deacetylase inhibitors.
[21765634] J Biomed Biotechnol 2011(-): 514261 (2011)

Beyond histone and deacetylase: an overview of cytoplasmic histone deacetylases and their nonhistone substrates.
[21234400] J Biomed Biotechnol 2011(-): 146493 (2011)

The role of HDACs inhibitors in childhood and adolescence acute leukemias.
[21318168] J Biomed Biotechnol 2011(-): 148046 (2011)

Histone deacetylase inhibitors: the epigenetic therapeutics that repress hypoxia-inducible factors.
[21151670] J Biomed Biotechnol 2011(-): 197946 (2011)

Histone deacetylase inhibitors in the treatment of hematological malignancies and solid tumors.
[21188171] J Biomed Biotechnol 2011(-): 475641 (2011)

Regulating the regulators: the post-translational code of class I HDAC1 and HDAC2.
[21197454] J Biomed Biotechnol 2011(-): 690848 (2011)

Physiological roles of class I HDAC complex and histone demethylase.
[21049000] J Biomed Biotechnol 2011(-): 129383 (2011)

Rationale for possible targeting of histone deacetylase signaling in cancer diseases with a special reference to pancreatic cancer.
[20981265] J Biomed Biotechnol 2011(-): 315939 (2011)

Roles and targets of class I and IIa histone deacetylases in cardiac hypertrophy.
[21151616] J Biomed Biotechnol 2011(-): 928326 (2011)

Biological roles and mechanistic actions of co-repressor complexes.
[11865025] J Cell Sci 115(Pt 4): 689-98 (2002)

Epigenetic histone acetylation modifiers in vascular remodelling: new targets for therapy in cardiovascular disease.
[19147603] Eur Heart J 30(3): 266-77 (2009)

Targeting histone deacetylases as a multifaceted approach to treat the diverse outcomes of stroke.
[19478231] Stroke 40(8): 2899-905 (2009)

Isoform-selective histone deacetylase inhibitors.
[18568166] Chem Soc Rev 37(7): 1402-13 (2008)

Regulating histone acetyltransferases and deacetylases.
[14528264] EMBO Rep 4(10): 944-7 (2003)

Histone deacetylase inhibitors and hemoglobin F induction in beta-thalassemia.
[18617435] Int J Biochem Cell Biol 40(11): 2341-7 (2008)

Eloquent silence: developmental functions of Class I histone deacetylases.
[18929655] Curr Opin Genet Dev 18(5): 404-10 (2008)

Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: mechanisms and potential clinical implications.
[19509170] Clin Cancer Res 15(12): 3947-57 (2009)

Rational combinations using HDAC inhibitors.
[19509171] Clin Cancer Res 15(12): 3970-7 (2009)

Clinical studies of histone deacetylase inhibitors.
[19509172] Clin Cancer Res 15(12): 3958-69 (2009)

Targeting epigenetic abnormalities with histone deacetylase inhibitors.
[16826577] Cancer 107(4): 832-40 (2006)

Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential?
[18728657] Br J Cancer 99(5): 689-94 (2008)

Histone deacetylases (HDACs): characterization of the classical HDAC family.
[12429021] Biochem J 370(Pt 3): 737-49 (2003)

The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men.
[18292778] Nat Rev Mol Cell Biol 9(3): 206-18 (2008)

Class IIA HDACs in the regulation of neurodegeneration.
[17981613] Front Biosci 13(-): 1072-82 (2008)

Targeting inflammation in heart failure with histone deacetylase inhibitors.
[21267510] Mol Med 17(5-6): 434-41 (2011)

Histone deacetylase inhibitors as therapeutic agents for acute central nervous system injuries.
[21274503] Mol Med 17(5-6): 448-56 (2011)

Histone deacetylase (HDAC) inhibition as a novel treatment for diabetes mellitus.
[21274504] Mol Med 17(5-6): 378-90 (2011)

HDAC inhibition and graft versus host disease.
[21298214] Mol Med 17(5-6): 404-16 (2011)

Histone deacetylase inhibitors in the treatment of muscular dystrophies: epigenetic drugs for genetic diseases.
[21308150] Mol Med 17(5-6): 457-65 (2011)

HDAC inhibition in rheumatoid arthritis and juvenile idiopathic arthritis.
[21308151] Mol Med 17(5-6): 397-403 (2011)

HDAC inhibition in lupus models.
[21327298] Mol Med 17(5-6): 417-25 (2011)

Inhibition of histone deacetylases in inflammatory bowel diseases.
[21365125] Mol Med 17(5-6): 426-33 (2011)

The therapeutic potential of HDAC inhibitors in the treatment of multiple sclerosis.
[21373721] Mol Med 17(5-6): 442-7 (2011)

Histone deacetylase inhibitors for purging HIV-1 from the latent reservoir.
[21424110] Mol Med 17(5-6): 466-72 (2011)

Targeting tumor angiogenesis with histone deacetylase inhibitors.
[19111391] Cancer Lett 280(2): 145-53 (2009)

Multiple roles of HDAC inhibition in neurodegenerative conditions.
[19775759] Trends Neurosci 32(11): 591-601 (2009)

Rational development of histone deacetylase inhibitors as anticancer agents: a review.
[15955865] Mol Pharmacol 68(4): 917-32 (2005)

Epigenetic therapy: targeting histones and their modifications in human disease.
[21426003] Future Med Chem 2(4): 543-8 (2010)

Immunomodulatory effects of deacetylase inhibitors: therapeutic targeting of FOXP3+ regulatory T cells.
[19855427] Nat Rev Drug Discov 8(12): 969-81 (2009)

Macrocyclic histone deacetylase inhibitors.
[20536416] Curr Top Med Chem 10(14): 1423-40 (2010)

Computational studies on the histone deacetylases and the design of selective histone deacetylase inhibitors.
[19355989] Curr Top Med Chem 9(3): 241-56 (2009)

HDAC inhibitors and neurodegeneration: at the edge between protection and damage.
[20123018] Pharmacol Res 62(1): 11-7 (2010)

Putting the 'HAT' back on survival signalling: the promises and challenges of HDAC inhibition in the treatment of neurological conditions.
[19388875] Expert Opin Investig Drugs 18(5): 573-84 (2009)

Explorative study on isoform-selective histone deacetylase inhibitors.
[19721249] Chem Pharm Bull (Tokyo) 57(9): 897-906 (2009)

Role of HDAC1 in senescence, aging, and cancer.
[19818845] Exp Gerontol 45(4): 279-85 (2010)

Benefits of histone deacetylase inhibitors for acute brain injury: a systematic review of animal studies.
[20831615] J Neurochem 115(4): 806-13 (2010)

Histone deacetylase in carcinogenesis and its inhibitors as anti-cancer agents.
[12542981] J Biochem Mol Biol 36(1): 110-9 (2003)

Histone deacetylase inhibitors: Potential in cancer therapy.
[19459166] J Cell Biochem 107(4): 600-8 (2009)

A work in progress: the clinical development of histone deacetylase inhibitors.
[18487953] Epigenetics 3(3): 164-71 (2008)

Down-regulation of UHRF1, associated with re-expression of tumor suppressor genes, is a common feature of natural compounds exhibiting anti-cancer properties.
[21496237] J Exp Clin Cancer Res 30(-): 41 (2011)

Dietary agents as histone deacetylase inhibitors.
[16652377] Mol Carcinog 45(6): 443-6 (2006)

MTA family of coregulators in nuclear receptor biology and pathology.
[18174918] Nucl Recept Signal 5(-): e010 (2007)

Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy.
[21258646] Clin Epigenetics 1(3-4): 117-136 (2010)

Histone deacetylase inhibitors in the therapy of cancer: much to learn.
[22122077] Epigenomics 2(6): 723-5 (2010)

Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect.
[21161327] Invest New Drugs 28 Suppl 1(): S3-20 (2010)

Histone deacetylase inhibitors in Hodgkin lymphoma.
[21127943] Invest New Drugs 28 Suppl 1(): S21-7 (2010)

Deactylase inhibition in myeloproliferative neoplasms.
[21127942] Invest New Drugs 28 Suppl 1(): S50-7 (2010)

The DAC system and associations with multiple myeloma.
[21120582] Invest New Drugs 28 Suppl 1(): S28-35 (2010)

Histone deacetylase signaling in cardioprotection.
[24310814] Cell Mol Life Sci 71(9):1673-90 (2014)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Fatal error: Uncaught Error: Call to undefined function mysql_connect() in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Histone deacetylase.php:92 Stack trace: #0 {main} thrown in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Histone deacetylase.php on line 92